Marinus Pharma Stock (NASDAQ:MRNS), Analyst Ratings, Price Targets, Predictions

The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by Truist Securities on April 17, 2024. The analyst firm set a price target for $10.00 expecting MRNS to rise to within 12 months (a possible 560.07% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by Truist Securities, and Marinus Pharma maintained their buy rating.

There is no last upgrade for Marinus Pharma.

The last downgrade for Marinus Pharmaceuticals Inc happened on April 16, 2024 when Baird changed their price target from $20 to $2 for Marinus Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.

While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a maintained with a price target of $25.00 to $10.00. The current price Marinus Pharma (MRNS) is trading at is $1.52, which is out of the analyst’s predicted range.